Combined treatment with a CXCL12 analogue and antibiotics improves survival and neutrophil recruitment and function in murine sepsis.

Previous studies demonstrated that the CXCL12 peptide analogue CTCE-0214 (CTCE) has beneficial effects in experimental sepsis induced by cecal ligation and puncture (CLP). We examined the hypothesis that CTCE recruits neutrophils (PMN) to the site of infection, enhances PMN function and improves survival of mice in CLP-induced sepsis with antibiotic treatment. Septic mice (n=15) were administered imipenem (25mg/kg) and CTCE (10 mg/kg) subcutaneously vs. vehicle control at designated intervals post-CLP. CTCE treatment increased PMN recruitment in CLP-induced sepsis as evidenced by increased PMN in blood by 2.4±0.6 fold at 18h, 2.9±0.6 fold at 24h, respectively and in peritoneal fluid by 2.0±0.2 fold at 24h vs. vehicle control. CTCE treatment reduced bacterial invasion in blood (CFU decreased 77±11%), peritoneal fluid (CFU decreased 78±9%) and lung (CFU decreased 79±8% vs. CLP vehicle). The improved PMN recruitment and bacterial clearance correlated with reduced mortality with CTCE treatment (20% vs. 67% vehicle controls). In vitro studies support the notion that CTCE augments PMN function by enhancing phagocytic activity (1.25±0.02 fold), increasing intracellular production of ROS (32±4%) and improving bacterial killing (CFU decreased 27±3%). These composite findings support the hypothesis that specific CXCL12 analogues with ancillary antibiotic treatment are beneficial in experimental sepsis, in part, by augmenting PMN recruitment and function. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.